Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(170 produits)
- ATM/ATR(72 produits)
- ADN-PK(49 produits)
- EGFR(581 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(231 produits)
- S6 Kinase(6 produits)
- gsk-3(109 produits)
- mTOR(163 produits)
Affichez 2 plus de sous-catégories
993 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK-3β inhibitor 26
CAS :GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.Formule :C15H11N3O3Couleur et forme :SolidMasse moléculaire :281.266EGFR-IN-147
CAS :EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275GSK3β-IN-2
CAS :GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.Formule :C25H18N4OCouleur et forme :SolidMasse moléculaire :390.4375-Bromo-3-indoxylacetate
CAS :5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.Formule :C10H8BrNO2Couleur et forme :SolidMasse moléculaire :254.08NU5455
CAS :NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.Formule :C34H33N3O5SCouleur et forme :SolidMasse moléculaire :595.71EG31
CAS :EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25DNA-PK-IN-9
DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.Formule :C21H21N5O2Couleur et forme :SolidMasse moléculaire :375.42PI3K-IN-23
PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).Formule :C24H33NO4SCouleur et forme :SolidMasse moléculaire :431.59BAY-091
CAS :BAY-091 is a novel potent and highly selective PIP4K2A kinase inhibitor.Formule :C26H21FN4O2Degré de pureté :97.66% - 99.23%Couleur et forme :SoildMasse moléculaire :440.47Ref: TM-T60147
1mg78,00€5mg168,00€10mg269,00€25mg427,00€50mg610,00€100mg820,00€500mgÀ demander1mL*10mM (DMSO)178,00€SIK2/3-IN-1
CAS :SIK2/3-IN-1 (Compound 7S) is an orally active and selective inhibitor of SIK2/3. It significantly inhibits tumor growth without causing weight loss in the MV4-11 AML mouse CDX model. SIK2/3-IN-1 is applicable for research in MEF2C-dependent acute myeloid leukemia.Formule :C20H19F3N6O2Couleur et forme :SolidMasse moléculaire :432.399Lys(CO-C3-p-I-Ph)-O-tBu
CAS :Lys(CO-C3-p-I-Ph)-O-tBu, a pharmacokinetic modifier (PK modifier), enhances the pharmacokinetic properties of PSMA ligand molecules by increasing their residence time in plasma through improved binding to albumin and reducing absorption by the salivary glands, potentially extending the active compound's half-life. Moreover, Ac-PSMA-trillium is an effective PSMA-targeting compound for various biological applications when modified with different radioactive isotopes. When labeled with 111 In, it serves as a DOTA chelating agent and imaging agent. Alternatively, when labeled with 225 Ac, it acts as a Macropa chelator for targeted radionuclide therapy (TRT) in researching metastatic castration-resistant prostate cancer (mCRPC) [1] [2].Formule :C20H31IN2O3Couleur et forme :SolidMasse moléculaire :474.38SIK2-IN-3
CAS :SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.Formule :C23H24N6O2Couleur et forme :SolidMasse moléculaire :416.48JBJ-02-112-05
CAS :JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54Vps34-IN-3
Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .Formule :C14H20N4O2Couleur et forme :SolidMasse moléculaire :276.33HER2-IN-8
CAS :HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27PF-5177624
CAS :PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.Formule :C25H25FN8O2Couleur et forme :SolidMasse moléculaire :488.52Vulolisib
CAS :Vulolisib inhibits PI3K (α: IC50 0.2nM, β: 168nM, γ: 90nM, δ: 49nM), taken orally with anti-cancer properties.Formule :C18H19F2N5O3SCouleur et forme :SolidMasse moléculaire :423.44EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.97EGFR-IN-38
CAS :EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96
